Essex Investment Management Co. LLC acquired a new stake in shares of Artivion, Inc. (NYSE:AORT – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 68,210 shares of the company’s stock, valued at approximately $1,034,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in Artivion by 0.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 317,995 shares of the company’s stock valued at $4,821,000 after purchasing an additional 2,659 shares during the period. First Eagle Investment Management LLC raised its stake in Artivion by 37.3% during the 3rd quarter. First Eagle Investment Management LLC now owns 526,528 shares of the company’s stock valued at $7,982,000 after purchasing an additional 143,146 shares during the period. Spire Wealth Management acquired a new stake in Artivion during the 3rd quarter valued at $159,000. New York State Common Retirement Fund raised its stake in Artivion by 25.0% during the 3rd quarter. New York State Common Retirement Fund now owns 15,009 shares of the company’s stock valued at $228,000 after purchasing an additional 2,999 shares during the period. Finally, Barclays PLC raised its stake in Artivion by 17.7% during the 3rd quarter. Barclays PLC now owns 23,025 shares of the company’s stock valued at $348,000 after purchasing an additional 3,458 shares during the period. Institutional investors and hedge funds own 83.32% of the company’s stock.
Artivion Stock Up 1.0 %
NYSE AORT opened at $17.16 on Monday. Artivion, Inc. has a 1-year low of $11.44 and a 1-year high of $19.00. The company has a quick ratio of 3.43, a current ratio of 4.86 and a debt-to-equity ratio of 1.14. The firm’s fifty day simple moving average is $17.79 and its 200-day simple moving average is $16.23.
Insider Transactions at Artivion
Analyst Ratings Changes
Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Artivion in a research note on Thursday, December 7th.
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.
- Five stocks we like better than Artivion
- What to Know About Investing in Penny Stocks
- Uber quadruples EPS estimates, but is growth decelerating?
- What is a buyback in stocks? A comprehensive guide for investors
- 3 stocks set to benefit from record Valentine’s Day spending
- Earnings Per Share Calculator: How to Calculate EPS
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.